Page 6,949«..1020..6,9486,9496,9506,951..6,9606,970..»

Advanced Cell Technology and PharmAthene Poised to Benefit From Positive Legislation

Posted: Published on March 29th, 2012

NEW YORK, NY--(Marketwire -03/28/12)- Biotechnology stocks have been on an impressive run this year as favorable legislation out of Washington is allowing biotech companies of all sizes to more easily navigate regulations. Five Star Equities examines the outlook for companies in the Biotechnology industry and provides equity research on Advanced Cell Technology Inc. (OTC.BB: ACTC.OB - News) and PharmAthene Inc. (AMEX: PIP - News). Access to the full company reports can be found at: http://www.fivestarequities.com/ACTC http://www.fivestarequities.com/PIP The Biotechnology Industry Organization (BIO) recently applauded the House Energy and Commerce Committee's passage of the Medicare Decisions Accountability Act, H.R. 452, which would repeal the Independent Payment Advisory Board (IPAB) established in the health care reform law. BIO also issued a press release applauding the Senate on the passage of H.R. 3606, the Jumpstart Our Business Startups (JOBS) Act. The JOBS Act creates an "on-ramp" to the public market for emerging growth companies, allowing them five years to focus on conducting critical research that can lead to cures for debilitating diseases before having to divert funds to costly regulations, BIO reports. Five Star Equities releases regular market updates on the biotechnology industry so investors can stay ahead of the crowd and make the … Continue reading →

Comments Off on Advanced Cell Technology and PharmAthene Poised to Benefit From Positive Legislation

Stem cell therapy for the repair of myocardium in heart failure patients – Video

Posted: Published on March 29th, 2012

28-03-2012 10:17 Dr Joshua Hare is Professor of Medicine and Director of the Interdisciplinary Stem Cell Institute at the University of Miami. The interview was conducted on 25 March 2012 at the American College of Cardiology's (ACC's) 61st Annual Scientific Session & Expo in Chicago. See more ACC.12 Coverage: http://www.getinsidehealth.com Go here to see the original: Stem cell therapy for the repair of myocardium in heart failure patients - Video … Continue reading →

Comments Off on Stem cell therapy for the repair of myocardium in heart failure patients – Video

CEO of stem cell company responds to FDA warning letter

Posted: Published on March 29th, 2012

The head of a stem cell company has responded to a warning letter issued by the U.S. Food and Drug Administration citing several violations at the company which derives stem cells from adipose tissue or body fat. Dr. Steven Victor of IntelliCell BioSciences said it would be moving to a new facility next month that it believes will address the current good manufacturing practice issues referred to in the warning letter It has also hired consultants with FDA compliance experience that will help bring its new facilities in compliance with the FDA. Victor added that the company will address all of the FDAs observations on April 3. The New York company received a warning letter dated March 13 that was published on the FDAs website yesterday. The letter said that the process that the company uses to produce stem cells from adipose tissue did not meet the FDAs definition of minimal manipulation for structural tissue such as adipose tissue. See original here: CEO of stem cell company responds to FDA warning letter … Continue reading →

Posted in Stem Cell Human Trials | Comments Off on CEO of stem cell company responds to FDA warning letter

Neuralstem ALS Stem Cell Trial Interim Results Reported in the Journal, STEM CELLS

Posted: Published on March 29th, 2012

ROCKVILLE, Md., March 28, 2012 /PRNewswire/ --Neuralstem, Inc. (NYSE Amex: CUR) announced that safety results from the first 12 patients with amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) to receive its stem cells were reported online in the peer-reviewed publication, STEM CELLS, on March 13th. "Lumbar Intraspinal Injection of Neural Stem Cells in Patients with ALS: Results of a Phase I Trial in 12 Patients" (http://www.ncbi.nlm.nih.gov/pubmed/22415942.1) reports that one patient has shown improvement in his clinical status, even though researchers caution that the study was not designed to show efficacy. Additionally, there was no evidence of accelerated disease progression due to the intervention in any of the 12 patients, who were followed from 6-18 months after they were transplanted with the cells. All of the patients, who received transplants in the lumbar (lower back) region, tolerated the treatment without any long-term complications related to either the surgery or the cells. (Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO ) The 12 patients, part of the ongoing Phase I trial to evaluate the safety of Neuralstem's stem cells and transplantation procedure in patients with ALS, were the first in the world to receive intraspinal stem cell injections. Results from these patients were also were reported at … Continue reading →

Comments Off on Neuralstem ALS Stem Cell Trial Interim Results Reported in the Journal, STEM CELLS

Advanced Cell Technology and PharmAthene Poised to Benefit From Positive Legislation

Posted: Published on March 29th, 2012

NEW YORK, NY--(Marketwire -03/28/12)- Biotechnology stocks have been on an impressive run this year as favorable legislation out of Washington is allowing biotech companies of all sizes to more easily navigate regulations. Five Star Equities examines the outlook for companies in the Biotechnology industry and provides equity research on Advanced Cell Technology Inc. (OTC.BB: ACTC.OB - News) and PharmAthene Inc. (AMEX: PIP - News). Access to the full company reports can be found at: http://www.fivestarequities.com/ACTC http://www.fivestarequities.com/PIP The Biotechnology Industry Organization (BIO) recently applauded the House Energy and Commerce Committee's passage of the Medicare Decisions Accountability Act, H.R. 452, which would repeal the Independent Payment Advisory Board (IPAB) established in the health care reform law. BIO also issued a press release applauding the Senate on the passage of H.R. 3606, the Jumpstart Our Business Startups (JOBS) Act. The JOBS Act creates an "on-ramp" to the public market for emerging growth companies, allowing them five years to focus on conducting critical research that can lead to cures for debilitating diseases before having to divert funds to costly regulations, BIO reports. Five Star Equities releases regular market updates on the biotechnology industry so investors can stay ahead of the crowd and make the … Continue reading →

Posted in Cell Medicine | Comments Off on Advanced Cell Technology and PharmAthene Poised to Benefit From Positive Legislation

Stem cell therapy for the repair of myocardium in heart failure patients – Video

Posted: Published on March 29th, 2012

28-03-2012 10:17 Dr Joshua Hare is Professor of Medicine and Director of the Interdisciplinary Stem Cell Institute at the University of Miami. The interview was conducted on 25 March 2012 at the American College of Cardiology's (ACC's) 61st Annual Scientific Session & Expo in Chicago. See more ACC.12 Coverage: http://www.getinsidehealth.com Read more from the original source: Stem cell therapy for the repair of myocardium in heart failure patients - Video … Continue reading →

Posted in Cell Therapy | Comments Off on Stem cell therapy for the repair of myocardium in heart failure patients – Video

NeoStem Announces Proposed Public Offering of Common Stock and Warrants

Posted: Published on March 29th, 2012

NEW YORK, March 28, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE Amex:NBS) ("NeoStem" or "the Company"), a leader in the cell therapy industry, today announced that it intends to offer and sell shares of its common stock and warrants in an underwritten public offering. All of the shares and warrants in the offering will be sold by NeoStem. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The securities will be issued pursuant to a prospectus supplement filed as part of an effective registration statement on Form S-3 previously filed with the Securities and Exchange Commission (SEC). Maxim Group LLC is acting as book-runner of the offering. A shelf registration statement relating to the securities was filed with the SEC, which became effective on June 13, 2011. A preliminary prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC's website at http://www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering may be obtained, when available, from Maxim Group LLC, 405 … Continue reading →

Posted in Cell Therapy | Comments Off on NeoStem Announces Proposed Public Offering of Common Stock and Warrants

In Brief: Side effects of Merck's experimental blood thinner could stall approval; Bristol-Myers Squibb may have …

Posted: Published on March 29th, 2012

A study of an experimental blood thinner from Merck showed that while the drug helped thwart heart attacks it raised the risk of brain bleeding, a side effect that could stymie its approval. The three-year study of 26,449 patients who had heart attack, stroke or leg artery disease, found those who got Mercks vorapaxar along with standard therapy were 13 percent less likely to have another heart attack or die from cardiovascular causes than those on standard treatment. More patients on the drug also had serious bleeding, according to data reported yesterday at the American College of Cardiology meeting in Chicago. The findings are unlikely to be good enough to get U.S. marketing approval, said Steven Nissen, a cardiologist at the Cleveland Clinic who wasnt involved in the study. New studies are needed to prove vorapaxar can be used in some patients without excess bleeding, he said. "The results are disappointing," Nissen said. "The bottom line is it is extremely difficult to make the case that the benefits exceed the risks here." In January 2011, Merck narrowed the scope of the trial to stop testing the drug in stroke patients and halted another vorapaxar trial entirely after doctors monitoring the … Continue reading →

Posted in Drug Side Effects | Comments Off on In Brief: Side effects of Merck's experimental blood thinner could stall approval; Bristol-Myers Squibb may have …

China BCT Announces Conference Call to Discuss Fourth Quarter and Full Year 2011 Results

Posted: Published on March 29th, 2012

LIUZHOU, China, March 28, 2012 /PRNewswire-Asia/ -- China BCT Pharmacy Group, Inc., (OTC BB: CNBI), ("China BCT" or the "Company"), a leading pharmaceutical distributor, retail pharmacy, and manufacturer of pharmaceutical products in Guangxi Province, China, today announced that it will conduct a conference call at 8:00 a.m. Eastern Time on Friday, March 30, 2012 to discuss its fourth quarter and full year 2011 results. Mr. Hui Tian Tang, Chief Executive Officer of the Company, and Ms. Shelly Zhang, Chief Financial Officer of the Company, will host the conference call. The Company will release its financial results for the fourth quarter and full year 2011 prior to the call. The conference call can be accessed by dialing 866-759-2078 (U.S. and Canada callers) or 706-643-0585 (international callers) and entering the conference ID 65662139 approximately five to ten minutes prior to the call. A replay will be available for two weeks starting on Friday, March 30, 2012 at 11:00 a.m. ET by dialing 855-859-2056 (U.S. and Canada callers) or 404-537-3406 (international callers) and entering the conference replay ID 65662139. About China BCT China BCT is engaged in pharmaceutical distribution, pharmacy retailing, and the manufacture of pharmaceuticals products through its subsidiaries Guangxi Liuzhou Baicaotang … Continue reading →

Posted in Wholesale Pharmacy | Comments Off on China BCT Announces Conference Call to Discuss Fourth Quarter and Full Year 2011 Results

Minneapolis firefighter from Coon Rapids charged in drug case

Posted: Published on March 29th, 2012

A Minneapolis firefighter set to go on trial next month for allegedly selling meth out of his Coon Rapids home has now been charged with selling dope from his fire station. Lawrence Anthony Wajda, 42 and a 20-year veteran of the Minneapolis Fire Department, was taken into custody during a search Wednesday, March 28, at Fire Station 19. Police said they got a warrant to search the station based on information from a confidential informant. A woman who was at the station at the time, Autumn Marie Ronning, 33, of Foreston, was also taken into custody and she, too, was charged Wednesday by Hennepin County prosecutors. Wajda is charged with fifth-degree drug possession, a felony. He's being held in the Hennepin County Adult Detention Facility with bail set at $10,000. Ronning is also being held, and Anoka and Ramsey counties have warrants out for her arrest in drug-related cases. The criminal complaint against Wajda says that when police searched him at the fire station, on the University of Minnesota campus, they found 0.5 gram (0.017 ounce) of methamphetamine. When they searched his sleeping area, they found a bag with a single pill they later determined was 3,4-methylenedioxymethamphetamine, more commonly known … Continue reading →

Posted in Drug Dependency | Comments Off on Minneapolis firefighter from Coon Rapids charged in drug case

Page 6,949«..1020..6,9486,9496,9506,951..6,9606,970..»